BRPI0512993A - uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto - Google Patents
uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de partoInfo
- Publication number
- BRPI0512993A BRPI0512993A BRPI0512993-1A BRPI0512993A BRPI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A
- Authority
- BR
- Brazil
- Prior art keywords
- contraception
- pharmaceutically useful
- antagonist
- female
- childbirth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE UM ANTAGONISTA DE PR, KIT FARMACEUTICAMENTE úTIL, E, MéTODO DE CONTRACEPçãO EM UMA FêMEA EM IDADE DE PARTO Um método de contracepção é fornecido que envolve a liberação de 21 a 27 dias consecutivos de um ou mais antagonistas de PR na ausência de uma progestina, estrogênio ou outro composto esteróide, seguido por 1 a 7 dias sem nenhum agente ativo. Também é descrito um kit farmaceuticamente útil para facilitar a liberação deste regime.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58588304P | 2004-07-07 | 2004-07-07 | |
US67613505P | 2005-04-29 | 2005-04-29 | |
PCT/US2005/023798 WO2006017075A1 (en) | 2004-07-07 | 2005-07-06 | Progesterone receptor antagonist contraceptive regimens and kits |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0512993A true BRPI0512993A (pt) | 2008-04-22 |
Family
ID=35106665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512993-1A BRPI0512993A (pt) | 2004-07-07 | 2005-07-06 | uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060009509A1 (pt) |
EP (1) | EP1773323A1 (pt) |
JP (1) | JP2008505906A (pt) |
KR (1) | KR20070039912A (pt) |
AR (1) | AR049664A1 (pt) |
AU (1) | AU2005271974A1 (pt) |
BR (1) | BRPI0512993A (pt) |
CA (1) | CA2571198A1 (pt) |
CR (1) | CR8800A (pt) |
EC (1) | ECSP077131A (pt) |
GT (1) | GT200500186A (pt) |
IL (1) | IL180238A0 (pt) |
MX (1) | MXPA06014580A (pt) |
NO (1) | NO20070377L (pt) |
PA (1) | PA8638501A1 (pt) |
PE (1) | PE20060485A1 (pt) |
RU (1) | RU2006144069A (pt) |
SV (1) | SV2006002166A (pt) |
TW (1) | TW200605880A (pt) |
WO (1) | WO2006017075A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
US20060009428A1 (en) | 2004-07-07 | 2006-01-12 | Wyeth | Cyclic progestin regimens and kits |
CA2573266C (en) | 2004-07-09 | 2011-11-08 | The Population Council, Inc. | Sustained release compositions containing progesterone receptor modulators |
GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
MY158766A (en) | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
EP2419108B1 (en) | 2009-04-14 | 2016-08-17 | Laboratoire HRA Pharma | Method for on-demand contraception |
AU2010261399B2 (en) | 2009-06-18 | 2014-07-17 | Pfizer Inc. | Bicyclic and tricyclic compounds as KAT II inhibitors |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
RU2015103694A (ru) | 2009-10-14 | 2015-06-27 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
MX343215B (es) | 2010-02-26 | 2016-10-27 | Xenon Pharmaceuticals Inc | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos. |
US9375437B2 (en) * | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
JP2013544277A (ja) | 2010-12-01 | 2013-12-12 | ファイザー・インク | Katii阻害剤 |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
EP2968367A1 (en) * | 2013-03-14 | 2016-01-20 | Laboratoire HRA Pharma | Method for scheduling ovulation |
TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
MX2017016823A (es) | 2015-06-22 | 2018-03-12 | Lipocine Inc | Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391907B1 (en) * | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6444668B1 (en) * | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
-
2005
- 2005-07-04 GT GT200500186A patent/GT200500186A/es unknown
- 2005-07-06 SV SV2005002166A patent/SV2006002166A/es not_active Application Discontinuation
- 2005-07-06 JP JP2007520434A patent/JP2008505906A/ja active Pending
- 2005-07-06 AU AU2005271974A patent/AU2005271974A1/en not_active Abandoned
- 2005-07-06 KR KR1020077000184A patent/KR20070039912A/ko not_active Application Discontinuation
- 2005-07-06 US US11/175,549 patent/US20060009509A1/en not_active Abandoned
- 2005-07-06 CA CA002571198A patent/CA2571198A1/en not_active Abandoned
- 2005-07-06 BR BRPI0512993-1A patent/BRPI0512993A/pt not_active Application Discontinuation
- 2005-07-06 EP EP05771038A patent/EP1773323A1/en not_active Withdrawn
- 2005-07-06 PE PE2005000782A patent/PE20060485A1/es not_active Application Discontinuation
- 2005-07-06 PA PA20058638501A patent/PA8638501A1/es unknown
- 2005-07-06 AR ARP050102807A patent/AR049664A1/es unknown
- 2005-07-06 MX MXPA06014580A patent/MXPA06014580A/es unknown
- 2005-07-06 RU RU2006144069/15A patent/RU2006144069A/ru not_active Application Discontinuation
- 2005-07-06 WO PCT/US2005/023798 patent/WO2006017075A1/en active Application Filing
- 2005-07-06 TW TW094122826A patent/TW200605880A/zh unknown
-
2006
- 2006-12-07 CR CR8800A patent/CR8800A/es not_active Application Discontinuation
- 2006-12-21 IL IL180238A patent/IL180238A0/en unknown
-
2007
- 2007-01-05 EC EC2007007131A patent/ECSP077131A/es unknown
- 2007-01-19 NO NO20070377A patent/NO20070377L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GT200500186A (es) | 2006-03-02 |
AR049664A1 (es) | 2006-08-23 |
KR20070039912A (ko) | 2007-04-13 |
WO2006017075A1 (en) | 2006-02-16 |
IL180238A0 (en) | 2007-07-04 |
ECSP077131A (es) | 2007-02-28 |
CA2571198A1 (en) | 2006-02-16 |
MXPA06014580A (es) | 2007-03-23 |
PE20060485A1 (es) | 2006-06-24 |
TW200605880A (en) | 2006-02-16 |
PA8638501A1 (es) | 2006-07-03 |
NO20070377L (no) | 2007-02-07 |
JP2008505906A (ja) | 2008-02-28 |
CR8800A (es) | 2007-08-28 |
RU2006144069A (ru) | 2008-08-20 |
AU2005271974A1 (en) | 2006-02-16 |
SV2006002166A (es) | 2006-05-09 |
EP1773323A1 (en) | 2007-04-18 |
US20060009509A1 (en) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0512993A (pt) | uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto | |
BRPI0512991A (pt) | uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto | |
ES2602823T3 (es) | Proceso para la preparación de drospirenona | |
PE20120860A1 (es) | Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco | |
PE20061415A1 (es) | Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
BRPI0505524A (pt) | método passìvel de utilização com um poço subterráneo, sistema passìvel de utilização com um poço subterráneo, e ferramenta passìvel de utilização com um poço subterráneo | |
AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
MX2009004616A (es) | Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente. | |
SG166107A1 (en) | Quadraphasic continuous graduated estrogen contraceptive | |
BRPI0514474A (pt) | multiparticulados | |
PE20060275A1 (es) | Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual | |
RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
BRPI0709057B8 (pt) | veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação | |
CL2007001961A1 (es) | Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo. | |
ITMI20040367A1 (it) | Processo per la preparazione di drospirenone | |
PE20080995A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
CO5631449A2 (es) | Nuevos esteres de etonogestrel | |
PE20090805A1 (es) | COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL | |
BR0215064A (pt) | Agonistas receptores seletivos de dopamina d3 para o tratamento de disfunção sexual | |
CL2004001317A1 (es) | Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h | |
PE20010579A1 (es) | Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos | |
DE602004018921D1 (de) | D dienogest | |
AR070302A1 (es) | Composicion farmaceutica de un sistema de liberacion vaginal de esteroides | |
BR0116127A (pt) | Composto, composição farmacêutica, uso de um composto, e, conjunto para a contracepção masculina | |
AR069195A1 (es) | Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |